Business
Todos Medical Enters Into Distribution Partnership with Osang Healthcare for the GeneFinder Plus™ COVID-19 Plus RealAMP Kit in the United States
Todos Medical Enters Into Distribution Partnership with Osang Healthcare for the GeneFinder Plus™ COVID-19 Plus RealAMP Kit in the United States.
About this update from Todos Medical Ltd.
[{"type":"text","content":"\n GeneFinder Plus has received Emergency Use Authorization from the US FDAAnalysis demonstrates GeneFinder Plus able to detect B.117, B.135, P1 and other variantsValidation ongoing with Saliva, Oropharyngeal and Nasal Sample collection NEW YORK, NY, REHOVAT, Israel, and SEOUL, South Korea, March 30, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), an in vitro diagnostics company focused on distributing comprehensive solutions for COVID-19 screening, diagnosis and immune support, as well as developing blood tests for early detection of cancer and Alzheimer’s disease, today announced that it has entered into a distribution partnership with Osang Healthcare (OHC) of South Korea, to distribute the GeneFinder™ COVID-19 Plus RealAMP Kit in the United States. Todos intends to make GeneFinder Plus the primary kit used for distribution in its fully integrated and automated COVID-19 PCR testing lab solutions. GeneFinder Plus has been granted Emergency Use Authorization (EUA) by the US FDA. “We are very pleased to enter into this partnership with OHC surrounding the distribution of GeneFinder Plus, one of the most sensitive kits to have received EUA from the US FDA,” said Gerald Commissiong, President & CEO of Todos Medical. “As PCR testing becomes more ingrained as the country re-opens, the emergence of new SARS-CoV-2 variants makes regulatory oversight of reagents that much more critical in the CLIA laboratory testing space. We intend to work closely with Osang to expand the use of GeneFinder Plus to include saliva testing, an area we see as critical for serial testing given its ease of use for children and healthy adults.” “The data indicate that GeneFinder Plus has an exquisite lower limit of detection (LOD), suggesting that it is able to identify SARS-CoV-2 at the very earliest stages of infection,” said Jorge Leon, PhD, Chief Medical Officer for Oncology and Infectious Diseases at Todos Medical. “As PCR testing in the United States moves towards a standard serial testing paradigm in school, offices, sporting leagues and other areas of society preparing to re-open, it will be more and more critical that highly sensitive tests are used in order to identify infection early, and thus limit the spread. The LOD of GeneFinder Plus,...